Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.43 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15129218 | 0.77 | P2RX7 (0.43) | P2RX7RAPGEF4EPHX2ALDH1A1HPGD | |
| SCHEMBL12734252 | 0.76 | P2RX7 (0.54) | P2RX7EPHX2 | |
| SCHEMBL10051058 | 0.76 | RAPGEF4 (0.41) | P2RX7RAPGEF4EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL14932492 | 0.76 | RAPGEF4 (0.41) | P2RX7RAPGEF4EPHX2SLC6A2SLC6A3 | |
| SCHEMBL110348 | 0.74 | KRAS (0.40) | P2RX7RAPGEF4ALDH1A1 | |
| SCHEMBL6151899 | 0.74 | RAPGEF4 (0.39) | P2RX7RAPGEF4ALDH1A1 | |
| SCHEMBL6355236 | 0.74 | RAPGEF4 (0.39) | P2RX7RAPGEF4EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL27129026 | 0.74 | RAPGEF4 (0.39) | P2RX7RAPGEF4EPHX2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL966799 | 0.72 | KRAS (0.39) | P2RX7RAPGEF4ALDH1A1 | |
| SCHEMBL20306076 | 0.72 | RAPGEF4 (0.38) | P2RX7RAPGEF4ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609868-B1 | TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | RAQUALIA PHARMA INC (JP) | 2023-10-18 | — | — | EP | disclosed |
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-06-26 | — | — | US | disclosed |
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005732-B2 | Potent non-urea inhibitors of soluble epoxide hydrolase | EPHX1, EPHX2, ECE1 | P2RX7 605/4885RAPGEF4 2540/4885EPHX2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.